Latest news with #Philips
RTÉ News
10 hours ago
- Business
- RTÉ News
Philips sees tariffs impact of €150-200m after US-EU deal
Dutch healthcare technology company Philips has today lowered its estimated impact from import tariffs after the US and the European Union agreed to the US imposing a 15% rate on most EU goods. The group, which sells products ranging from toothbrushes to medical imaging systems, said it expects an impact of €150-200m from the tariffs, lower than the €250-300m it estimated previously. The tariff impact "has evolved and continues to be dynamic", Philips said in a statement. The company also increased its core profit (EBITA) margin forecast to a range between 11.3% and 11.8% from its previous forecast of 10.8%-11.3%. Its second-quarter adjusted EBITA margin grew to 12.4%, beating analysts' average forecast of 9.9% in a company-provided consensus, while sales were in line with expectations at €4.3 billion. Philips operates through its Personal Health, Diagnosis & Treatment, and Connected Care segments. Its top selling products include image-guided and diagnostic systems, consumer electronics and appliances. The company said its comparable order intake grew by 6% in the quarter, citing the impact of innovations including AI-enabled diagnostic systems. The group also said it had signed a long-term deal with the Indonesian Ministry of Health for its Azurion image-guided therapy system for cardiac, stroke and cancer care.
Yahoo
10 hours ago
- Business
- Yahoo
Philips chops back US tariff bill
Dutch medical equipment manufacturer Philips said Tuesday that the impact of US tariffs would be much less than it initially estimated, sending its share price surging. The company had originally estimated in April that US tariffs could cost it 250 to 300 million euros this year after President Donald Trump unveiled a 20 percent tariff rate for goods from the European Union. Brussels and Washington reached a deal over the weekend that will see goods from the EU face a baseline 15 percent levy when imported into the United States. It said Tuesday it now expects between 150 and 200 million euros impact from US tariffs this year. Chief executive Roy Jakobs said Philips updated "the guidance because we have certainty now around what is happening between the EU and the US." Shares in Philips jumped more than 10 percent during morning trading, while the Amsterdam market rose around 0.4 percent overall. The trade deal has come under widespread criticism in Europe as having been lopsided, saddling its manufacturers with a costly 15 percent rate with little in return from the US as certainty is a relative concept given Trump's propensity to change positions. Jakobs said that certainty "is what we value in" in the deal, while acknowledging "it's a painful additional cost we have to carry". The company still targets a one to three percent increase in annual sales. Second quarter net profit fell by 47 percent to 240 million euros, but last year's performance was boosted by exceptional income from insurance payouts linked to long-running issues with its sleep apnoea machines. Sales slid by 2.8 percent to 4.3 billion euros, although they edged higher on a comparable basis that excludes currency changes. The company also noted orders rose by six percent on a comparable basis. The appreciation of the euro relative to the dollar and other currencies has been crimping the results of European companies as their revenues abroad result in fewer euros on the balance sheet. Long known for its light bulbs and television sets, the Dutch company has refocused its business towards medical equipment. sh/rl/yad
Free Malaysia Today
12 hours ago
- Business
- Free Malaysia Today
Philips chops back US tariff bill
Shares in Philips jumped more than 10% during morning trading. (EPA Images pic) AMSTERDAM : Dutch medical equipment manufacturer Philips said today that the impact of US tariffs would be much less than it initially estimated, sending its share price surging. The company had originally estimated in April that US tariffs could cost it €250 million to €300 million this year after President Donald Trump unveiled a 20% tariff rate for goods from the EU. Brussels and Washington reached a deal over the weekend that will see goods from the EU face a baseline 15% levy when imported into the US. It said today it now expects between €150 million and €200 million impact from US tariffs this year. Chief executive Roy Jakobs said Philips updated 'the guidance because we have certainty now around what is happening between the EU and the US.' Shares in Philips jumped more than 10% during morning trading, while the Amsterdam market rose around 0.4% overall. The trade deal has come under widespread criticism in Europe as having been lopsided, saddling its manufacturers with a costly 15% rate with little in return from the US as certainty is a relative concept given Trump's propensity to change positions. Jakobs said that certainty 'is what we value in' in the deal, while acknowledging 'it's a painful additional cost we have to carry'. The company still targets a one to 3% increase in annual sales. Second quarter net profit fell by 47% to €240 million, but last year's performance was boosted by exceptional income from insurance payouts linked to long-running issues with its sleep apnoea machines. Sales slid by 2.8% to €4.3 billion, although they edged higher on a comparable basis that excludes currency changes. The company also noted orders rose by 6% on a comparable basis. The appreciation of the euro relative to the dollar and other currencies has been crimping the results of European companies as their revenues abroad result in fewer euros on the balance sheet. Long known for its light bulbs and television sets, the Dutch company has refocused its business towards medical equipment.
The Independent
13 hours ago
- Health
- The Independent
Is the Philips sonicare 9900 prestige the ultimate travel companion?
Whether you're moving on from your manual or have decided your current model needs an upgrade, there's a world of choice when it comes to electric toothbrushes – and Philips is a leading brand in the crowded market. While some brushes feature an oscillating and rotating head, others use multiple sonic pulses to separate the plaque from the teeth. As the name suggests, all the brushes in the bestselling Philips sonicare range use the latter. In layman's terms, this means the brush head moves rapidly from side to side over the surfaces of the teeth, while sonic vibrations have an agitating effect on the mixture of toothpaste and fluids in the mouth, which in turn helps to loosen plaque. The 9900 prestige was the first electric toothbrush to combine this unique sonic approach with an app, run by Philips' Sense IQ technology. This provides real-time guidance on a number of criteria from duration and frequency, to pressure and position when brushing your teeth – and myriad brands have launched similar apps in the years since. As someone who takes oral health seriously and treats dental care as a non-negotiable part of my daily routine, I'm always on the lookout for tools that actually make a difference. I've tested a wide range of electric toothbrushes over the years – from stain busters to the most premium models on the market – so I've developed a sharp sense of what genuinely improves the brushing experience. That's why I was especially curious to try the Philips sonicare 9900 prestige, a toothbrush that costs as much as a porcelain crown – but will it save you that kind of expense in the long run? How I tested I've spent several weeks testing this toothbrush in order to really put it through its paces. Here's what I looked out for. Multiple testers: I'm an experienced electric toothbrush user and left my manual behind many years ago. So, I also enlisted the help of another tester who only recently started brushing their teeth with an electric. As a first-time user, I wanted to see how easy they got on with the Philips toothbrush, from the app to the brushing experience. App: Each of us spent a month with the electric toothbrush to get used to the product's app, testing the real-time guidance while assessing the model on from everything from duration and frequency, to pressure and position when brushing our teeth. Performance: Of course, the performance of the brush was all-important in testing. We wanted to notice any impact it had on our dental hygiene and how fresh and clean our mouths felt after brushing our teeth. Battery: It's annoying have to constantly charge your toothbrush, so we both considered how long the battery actually lasted (the brand claims it has a battery life of 14 days when used twice a day for two minutes each time) and how long it took to re-charge. Why you can trust IndyBest reviews Jon Axworthy is a writer with nearly three decades of experience. He has been contributing reviews to IndyBest since 2017, specialising in home, tech and garden. He applies the same rigorous testing approach to everything from grass strimmers to cordless drills and much more. Offering his honest opinions to help you find the best product, he's also reviewed countless electric toothbrushes, from Philips to Oral B.
Yahoo
13 hours ago
- Business
- Yahoo
Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott
The Europe defibrillator market, valued at USD 3.87 billion in 2024, is projected to reach USD 7.23 billion by 2033, with a CAGR of 7.2%. Growth drivers include rising cardiovascular diseases, technological advancements, and government initiatives to expand public defibrillator access. Key segments include implantable and external defibrillators with significant usage in hospitals, public, and home settings. The market faces challenges such as high device costs and regulatory complexities. Leading players like Medtronic and Philips are instrumental in market expansion through innovations and strategic partnerships across Europe. European Defibrillator Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Europe Defibrillator Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Europe defibrillator market achieved USD 3.87 billion in 2024 and is expected to expand to USD 7.23 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. The market is growing due to the growing prevalence of cardiovascular disease, raising awareness of emergency cardiac care, and technology advancements in defibrillators in hospitals, public areas, and homecare areas across Europe. A defibrillator is an emergency medical equipment that is intended to resuscitate a normal heartbeat by passing an electric shock or pulse through the heart. It is most commonly applied for the treatment of sudden cardiac arrest (SCA), which occurs when the heart suddenly fails to beat. Defibrillators are variously categorized into automated external defibrillators (AEDs), implantable cardioverter-defibrillators (ICDs), and wearable cardioverter defibrillators (WCDs), which each fulfill certain requirements in respective care Europe, demand and use of defibrillators have increased with the growing number of heart diseases and government efforts to place AEDs at public areas like airports, shopping malls, and stadiums. Strong healthcare facilities and public education campaigns regarding cardiac arrest and first response also characterize the region. Advances in technology, including user-friendly and portable AEDs, have also facilitated the adoption in both clinical and non-clinical settings. Consequently, defibrillators are now a part of emergency medical response systems in Driver in the Europe Defibrillator Market Increasing Incidence of Cardiovascular DiseasesEurope is experiencing a sharp rise in cardiovascular diseases, including arrhythmias and sudden cardiac arrest (SCA), which is driving the demand for defibrillators. Cardiovascular disease is still the primary cause of death throughout the region, according to the European Society of Cardiology. The risk factors are amplified also by the aging population and the lack of physical activity. This increasing number of patients calls for the widespread use of defibrillators in hospitals, ambulances, public areas, and even homes to provide timely intervention and enhance survival rates. This trend is in favor of market growth in various European nations, especially those with older populations such as Germany and Italy. Cardiovascular diseases (CVDs) are the most prevalent cause of disability and premature mortality in the European Region and are responsible for more than 42.5% of total annual deaths, equivalent to 10,000 deaths each Initiatives and Public Access ProgramsGovernments across Europe have put in place comprehensive initiatives to enhance access to lifesaving equipment such as AEDs. Several nations now require the placement of defibrillators in public areas, sports facilities, transportation centers, and schools. Training and public awareness activities conducted by health ministries and non-profit groups have also fostered community preparedness to manage cardiac emergencies. For example, France and the UK have focused on public access defibrillation (PAD) programs. These initiatives substantially enhance survival rates for out-of-hospital cardiac arrest, generating demand for simple-to-use external defibrillators and building a booming market for portable and fixed devices throughout the continent. In 2023, more than 500,000 people in Europe were trained in CPR and AED through certified programs, improving public preparedness for cardiac emergencies. The European Resuscitation Council worked with national health authorities to make AED training compulsory in workplaces with more than 50 employees to enhance emergency readiness across Developments and Product InnovationOngoing development of defibrillator technology, such as small form factors, Bluetooth connection, real-time data monitoring, and simplicity of operation, is driving adoption in both clinical and non-clinical environments in Europe. Companies are innovating voice-prompted, easy-to-use AEDs that can be used by the layperson, increasing usage in public and residential settings. The growth in remote monitoring and improved battery life has also increased appeal in chronic heart care with ICDs. Connectivity with hospital networks and EHRs even improves coordination of care. All these technology enhancements are crucial for the long-term development and competitiveness of the European market. Oct 2024, ZOLL, an Asahi Kasei company, announced the approval of the ZOLL AED Plus defibrillator under the EU Medical Device Regulation 2017/745. The ZOLL AED 3 received MDR approval in January in the Europe Defibrillator Market High Cost of Devices and Implant ProceduresDefibrillators, especially implantable ones, are often expensive, making them less accessible in regions with budget constraints or lower insurance penetration. The economic burden is not just the cost of the device but also its surgical implantation, post-surgical care, and replacement of the device. This economic barrier is especially important in Eastern Europe where reimbursement mechanisms are weaker. The large up-front investment asked of hospitals and healthcare systems could also preclude widespread use, particularly in rural or under-resourced healthcare systems. Consequently, cost remains a major barrier to broad market penetration in some regions of Complexity and Product Recall RiskEurope's stringent regulatory climate, although ensuring quality and safety, can retard product approvals and market access for new defibrillator technologies. Medical device makers have to deal with the convoluted Medical Device Regulation (MDR) system, adding compliance costs and time-to-market. In addition, previous recalls of products over battery failure or software problems have generated doubts over device reliability. Such recalls not only harm the brand image but also result in losses and lowered consumer confidence. The regulatory overburden and threat of technical defects pose consistent challenges to manufacturers and healthcare professionals in the entire European defibrillator Implantable Defibrillator MarketThe European implantable defibrillator market is increasing steadily with the increasing rates of chronic heart diseases, including arrhythmias and cardiomyopathy. Devices such as Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are widely employed to avoid sudden cardiac death in patients at high risk. The devices are being increasingly used in advanced cardiac care facilities, especially in Western Europe. Germany, France, and the UK have spearheaded this uptake because of their advanced healthcare infrastructure and reimbursement schemes. Improved battery life, remote monitoring capabilities, and miniaturized designs are rendering ICDs more efficient and External Defibrillator MarketExternal defibrillators, and more so Automated External Defibrillators (AEDs), are experiencing robust growth throughout Europe fueled by extensive public access programs. These easy-to-use, portable devices are increasingly being installed at public locations, schools, offices, and transit terminals to enhance response to sudden cardiac arrest emergencies. Demand is also supported by increasing awareness and government-supported programs. Manual and semi-automatic defibrillators continue to be essential in ambulances and emergency departments. The UK and France are aggressively encouraging the use of external defibrillators, while corporations and private institutions are also purchasing AEDs as part of workplace safety Hospital Defibrillator MarketHospitals continue to be the biggest end-user of defibrillators in Europe because of high levels of cardiac procedures and emergency interventions. High-end defibrillator devices for life-saving procedures are essential for advanced cardiac life support systems in operating theaters, emergency rooms, and intensive care units (ICUs). Both external and implantable defibrillators are implemented in hospitals across Europe, according to patient requirements. Clinical efficiency is boosted through the implementation of technologically sophisticated models with ECG monitoring, manual override, and automatic data logging. Germany, France, and the Netherlands are the leaders, with advanced hospital infrastructure and an increasing population of old age that requires round-the-clock cardiac monitoring. February 2024, Patients at Royal Papworth Hospital NHS Foundation Trust are the first in Europe, outside of clinical trials, to be fitted with a new implantable cardioverter-defibrillator (ICD) to correct irregular heart rhythms and avoid sudden cardiac Home Healthcare Defibrillator MarketThe home healthcare defibrillator market is picking up steam in Europe, driven by the growing population of older people and the shift towards managing chronic care at home. Portable and wearable AEDs, being simple to use, enable people with a history of cardiac conditions to react immediately to cardiac arrests. They are especially useful for patients with a risk of sudden cardiac arrest but not suitable for ICD implantation. The rise in the number of home care services, particularly in Western Europe, contributes to demand even further. Insurance coverage and the incorporation of telemedicine are also playing a significant role in fuelling the home-use defibrillator segment's growth throughout the region. Key Players Analysis: Overviews, Key Persons, Recent Developments, Revenue Medtronic Plc. Philips Healthcare Nihon Kohden Corporation Boston Scientific Corporation Stryker Corporation Asahi Kasei Corporation LivaNova PLC. Abbott Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $3.87 Billion Forecasted Market Value (USD) by 2033 $7.23 Billion Compound Annual Growth Rate 7.2% Regions Covered Europe Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Europe Defibrillator Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Product6.2 By End Users6.3 By Country7. Product7.1 Implantable Defibrillators7.2 External Defibrillators8. End User8.1 Hospital8.2 Pre-hospital8.3 Public Access Market8.4 Alternate Care Market8.5 Home Healthcare9. Country9.1 France9.2 Germany9.3 Italy9.4 Spain9.5 United Kingdom9.6 Belgium9.7 Netherlands9.8 Russia9.9 Poland9.10 Greece9.11 Norway9.12 Romania9.13 Portugal9.14 Rest of Europe10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Defibrillator Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
